Two girls with a neonatal screening-negative 21-hydroxylase deficiency requiring treatment with hydrocortisone for virilization in late childhood.

21-hydroxylase deficiency congenital adrenal hyperplasia neonatal screening premature birth secondary central precocious puberty

Journal

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
ISSN: 0918-5739
Titre abrégé: Clin Pediatr Endocrinol
Pays: Japan
ID NLM: 9433330

Informations de publication

Date de publication:
2021
Historique:
received: 07 02 2021
accepted: 20 04 2021
entrez: 21 7 2021
pubmed: 22 7 2021
medline: 22 7 2021
Statut: ppublish

Résumé

Herein, we report two girls with a neonatal screening (NS)-negative 21-hydroxylase deficiency (21-OHD) requiring treatment with hydrocortisone due to virilization that developed in late childhood. Patient 1 was born prematurely on the 30th gestational week with normal external genitalia at birth. She passed the NS for 21-OHD. At 6 yr of age, she was referred to a hospital for evaluation of premature pubarche and clitoromegaly. Her diagnosis was central precocious puberty, and GnRH agonist was initiated. However, her symptoms did not improve despite treatment for over 4 years. She was then referred to our hospital where she was diagnosed with 21-OHD. Although she was started on hydrocortisone therapy, her adult height reached only 140 cm (-3.4 SD). Patient 2 was delivered at 37 weeks of gestation and passed the NS for 21-OHD. She was referred to a hospital because of premature pubarche at the age of 6 yr. She was diagnosed with 21-OHD, and hydrocortisone replacement therapy was initiated. Her present height at 13 yr of age is 148 cm (-1.3 SD). These cases reminded us that the possibility of 21-OHD should be considered when patients show premature pubarche or precocious puberty, even if they passed the NS test for 21-OHD.

Identifiants

pubmed: 34285457
doi: 10.1297/cpe.30.143
pii: 2021-0013
pmc: PMC8267553
doi:

Types de publication

Case Reports

Langues

eng

Pagination

143-148

Informations de copyright

2021©The Japanese Society for Pediatric Endocrinology.

Déclaration de conflit d'intérêts

Tomonobu Hasegawa discloses the following financial relationships: receipt of scholarship donations from Novo Nordisk Pharma Ltd. and JCR Pharmaceuticals Co., Ltd. Keiichi Ozono discloses the following financial relationships: receipt of lecture fees from Kyowa Kirin Co., Ltd., Alexion Pharmaceuticals, Inc., and Novo Nordisk Pharma Ltd.

Références

Clin Endocrinol (Oxf). 2002 Feb;56(2):231-8
pubmed: 11874415
Lancet. 2005 Jun 18-24;365(9477):2125-36
pubmed: 15964450
BMC Pediatr. 2015 Dec 15;15:209
pubmed: 26671474
Arch Pediatr Adolesc Med. 2012 Feb;166(2):113-20
pubmed: 22312171
J Clin Endocrinol Metab. 2018 Nov 1;103(11):4043-4088
pubmed: 30272171
Endocr J. 2015;62(3):277-82
pubmed: 25736066
JAMA Pediatr. 2014 Jun;168(6):567-74
pubmed: 24733564
Eur J Endocrinol. 2019 Mar;180(3):R127-R145
pubmed: 30566904
Lancet Diabetes Endocrinol. 2013 Sep;1(1):35-42
pubmed: 24622265
J Clin Res Pediatr Endocrinol. 2017 Mar 1;9(1):1-7
pubmed: 27354284
Hormones (Athens). 2015 Apr-Jun;14(2):265-71
pubmed: 25553759
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2611-6
pubmed: 23359698
N Engl J Med. 2003 Aug 21;349(8):776-88
pubmed: 12930931
Rev Endocr Metab Disord. 2009 Mar;10(1):77-82
pubmed: 18690539
Nat Rev Endocrinol. 2009 Sep;5(9):490-8
pubmed: 19690561
J Clin Endocrinol Metab. 2010 Sep;95(9):4133-60
pubmed: 20823466
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2695-2700
pubmed: 30779848
Eur J Endocrinol. 2009 Aug;161(2):285-92
pubmed: 19451212
J Clin Endocrinol Metab. 1977 Nov;45(5):1003-8
pubmed: 925125
Pediatrics. 2001 Dec;108(6):1320-4
pubmed: 11731654
Eur J Endocrinol. 2005 Jun;152(6):869-74
pubmed: 15941926
Clin Pediatr Endocrinol. 2015 Jul;24(3):77-105
pubmed: 26594092
Pediatr Endocrinol Rev. 2012 Oct;10 Suppl 1:72-8
pubmed: 23330248
J Pediatr. 2014 May;164(5):1136-40
pubmed: 24582106
Clin Endocrinol (Oxf). 2002 Nov;57(5):669-76
pubmed: 12390343
Eur J Pediatr. 2008 Apr;167(4):479-81
pubmed: 17516082
Pediatrics. 1988 Jun;81(6):866-74
pubmed: 3259306

Auteurs

Shinsuke Onuma (S)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Tomoya Fukuoka (T)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Yoko Miyoshi (Y)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Department of Health and Nutrition, Faculty of Health and Nutrition, Osaka Shoin Women's University, Osaka, Japan.

Miho Fukui (M)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Yoshinori Satomura (Y)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Kie Yasuda (K)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Takeshi Kimura (T)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Makiko Tachibana (M)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Kazuhiko Bessho (K)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Takehisa Yamamoto (T)

Department of Pediatrics, Minoh City Hospital, Osaka, Japan.

Hiroyuki Tanaka (H)

Department of Pediatrics, Okayama Saiseikai General Hospital, Okayama, Japan.

Noriyuki Katsumata (N)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Maki Fukami (M)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Tomonobu Hasegawa (T)

Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.

Keiichi Ozono (K)

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Classifications MeSH